Artificial intelligence in sickle disease

IF 6.9 2区医学 Q1 HEMATOLOGY

Blood Reviews Pub Date : 2023-09-01 DOI:10.1016/j.blre.2023.101102

Ahmed Adel Elsabagh , Mohamed Elhadary , Basel Elsayed , Amgad Mohamed Elshoeibi , Khaled Ferih , Rasha Kaddoura , Salam Alkindi , Awni Alshurafa , Mona Alrasheed , Abdullah Alzayed , Abdulrahman Al-Abdulmalek , Jaffer Abduljabber Altooq , Mohamed Yassin

{"title":"Artificial intelligence in sickle disease","authors":"Ahmed Adel Elsabagh , Mohamed Elhadary , Basel Elsayed , Amgad Mohamed Elshoeibi , Khaled Ferih , Rasha Kaddoura , Salam Alkindi , Awni Alshurafa , Mona Alrasheed , Abdullah Alzayed , Abdulrahman Al-Abdulmalek , Jaffer Abduljabber Altooq , Mohamed Yassin","doi":"10.1016/j.blre.2023.101102","DOIUrl":null,"url":null,"abstract":"<div><p>Artificial intelligence (AI) is rapidly becoming an established arm in medical sciences and clinical practice in numerous medical fields. Its implications have been rising and are being widely used in research, diagnostics, and treatment options for many pathologies, including sickle cell disease (SCD). AI has started new ways to improve risk stratification and diagnosing SCD complications early, allowing rapid intervention and reallocation of resources to high-risk patients. We reviewed the literature for established and new AI applications that may enhance management of SCD through advancements in diagnosing SCD and its complications, risk stratification, and the effect of AI in establishing an individualized approach in managing SCD patients in the future. <strong>Aim</strong>: to review the benefits and drawbacks of resources utilizing AI in clinical practice for improving the management for SCD cases.</p></div>","PeriodicalId":56139,"journal":{"name":"Blood Reviews","volume":"61 ","pages":"Article 101102"},"PeriodicalIF":6.9000,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"4","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Blood Reviews","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0268960X23000632","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 4

Abstract

Artificial intelligence (AI) is rapidly becoming an established arm in medical sciences and clinical practice in numerous medical fields. Its implications have been rising and are being widely used in research, diagnostics, and treatment options for many pathologies, including sickle cell disease (SCD). AI has started new ways to improve risk stratification and diagnosing SCD complications early, allowing rapid intervention and reallocation of resources to high-risk patients. We reviewed the literature for established and new AI applications that may enhance management of SCD through advancements in diagnosing SCD and its complications, risk stratification, and the effect of AI in establishing an individualized approach in managing SCD patients in the future. Aim: to review the benefits and drawbacks of resources utilizing AI in clinical practice for improving the management for SCD cases.

查看原文本刊更多论文

镰状病中的人工智能

人工智能（AI）正在迅速成为医学科学和众多医学领域临床实践中的一个重要分支。它的意义一直在上升，并被广泛用于许多病理学的研究、诊断和治疗选择，包括镰状细胞病（SCD）。人工智能已经开始了改善风险分层和早期诊断SCD并发症的新方法，允许快速干预并将资源重新分配给高危患者。我们回顾了现有和新的人工智能应用的文献，这些应用可能通过诊断SCD及其并发症、风险分层以及人工智能在未来建立个性化方法管理SCD患者方面的作用来加强SCD的管理。目的：回顾临床实践中利用人工智能资源改善SCD病例管理的优缺点。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Blood Reviews 医学-血液学

CiteScore

13.80

自引率

1.40%

发文量

期刊介绍： Blood Reviews, a highly regarded international journal, serves as a vital information hub, offering comprehensive evaluations of clinical practices and research insights from esteemed experts. Specially commissioned, peer-reviewed articles authored by leading researchers and practitioners ensure extensive global coverage across all sub-specialties of hematology.